Medical Management of Parkinson’s Disease: Focus on Neuroprotection
Author Information
Author(s): Boll Marie-Catherine, Alcaraz-Zubeldia Mireya, Rios Camilo
Primary Institution: National Institute of Neurology and Neurosurgery, Mexico
Hypothesis
The study investigates the neuroprotective properties of various drugs in the treatment of Parkinson's disease.
Conclusion
Neuroprotection in Parkinson's disease has not been solidly achieved, but some treatments show promise in modifying disease progression.
Supporting Evidence
- Selegiline and rasagiline have shown neuroprotective efficacy in preclinical studies.
- The DATATOP study indicated that deprenyl significantly delayed the onset of disability requiring levodopa therapy.
- Rasagiline may slow the rate of progression of Parkinson's disease when used early.
Takeaway
This study looks at how certain medicines might help protect the brain in people with Parkinson's disease, but we still need more proof that they work.
Methodology
The study reviews various compounds and their neuroprotective effects based on preclinical and clinical trials.
Potential Biases
Confounding effects from symptomatic treatments may obscure the true neuroprotective benefits of the drugs.
Limitations
No drug has been established as a neuroprotective agent in human subjects, and results may be confounded by symptomatic effects.
Participant Demographics
The study involved patients with early Parkinson's disease.
Statistical Information
P-Value
p=0.006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website